This is an open-label, non-controlled, non-randomized study to investigate the long-lasting
radiolabeled somatostatin analogue based peptide receptor radionuclide therapy and evaluation
safety and dosimetry of 177Lu-DOTA-EB-TATE in patients with advanced metastatic
neuroendocrine tumors. A single dose of 0.50GBq-0.70GBq (13.5-18.9 mCi) of 177Lu-DOTA-EB-TATE
will be injected intravenously. and monitored at 2, 24, 72,120 and 168 hours post-injection
with semiquantitative method based on quantitative single-photon emission computed
tomography/computed tomography (SPECT/CT) performance.
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Peking Union Medical College Hospital, Beijing, Beijing, China
Peking Union Medical College Hospital
Beijing, Beijing, 100730